Related Experiment Videos
[Obstructive jaundice caused by hepatocellular carcinoma].
Oreste Nardello1, Gian Paolo Farina, Marino Cagetti
1Università degli studi di Cagliari, Dipartimento chirurgico, materno-infantile e scienze delle immagini, Istituto di Chirurgia, Clinica Chirurgica. orenar@tiscali.it
Annali Italiani Di Chirurgia
|July 11, 2006
Summary
Hepatocellular carcinoma (HCC) can present with early or late jaundice. Early obstructive jaundice indicates a small tumor, enabling timely diagnosis and better outcomes, while late jaundice signals advanced disease and poor prognosis.
Area of Science:
- Hepatology
- Oncology
- Gastroenterology
Background:
- Hepatocellular carcinoma (HCC) is a primary liver cancer with significant global health implications.
- Obstructive jaundice is a critical clinical sign that can complicate the presentation of various intra-abdominal pathologies, including liver cancer.
- Understanding the timing and nature of jaundice in HCC is crucial for diagnosis and prognosis.
Observation:
- Two patients with hepatocellular carcinoma (HCC) presented with obstructive jaundice, prompting a review of literature and clinical cases.
- The study observed two distinct patterns of jaundice in the context of HCC evolution: 'early' and 'late'.
Findings:
- Late jaundice in HCC is associated with advanced disease, characterized by tumor invasion of the biliary tree and/or liver failure due to cirrhosis, portending a fatal prognosis.
- Early jaundice, resulting from small tumors obstructing the bile duct, signifies a better prognostic outlook.
- Early obstructive jaundice, detected alongside imaging techniques, facilitates early HCC diagnosis, crucial for effective palliation or potential cure.
Implications:
- The presence and type of jaundice in HCC patients can serve as an important prognostic indicator.
- Early diagnosis of HCC, facilitated by recognizing early obstructive jaundice, is key to improving patient management and outcomes.
- This study underscores the importance of investigating jaundice in liver disease patients for timely cancer detection and intervention.